Expert Interview
Discussing Gilead’s Trodelvy for the treatment of HR+/HER2- Metastatic Breast Cancer, Following EMA Approval; PDUFA due February
Ticker(s): GILDAn oncologist with experience in treating HR+/HER2- Metastatic Breast Cancer.
Please describe your practice as a clinician,how many patients with HR+/HER2- Metastatic Breast Cancer do you see on a yearly basis? Can you describe the standard of care, and take us through the most promising upcoming treatments?
How much of an unmet need is there for HR+/HER2- Metastatic Breast Cancer? How competitive and effective is Endocrine therapy or Chemotherapy?
Could you walk us through the details regarding Trodelvy’s mechanism of action and composition, and how that translate into beneficial patient outcomes:- Monoclonal antibody: The humanized monoclonal antibody, hRS7 IgG1κ, that binds to Trop-2, a transmembrane calcium signal transducer that is overexpressed in many epithelial cancers, including triple-negative breast cancer (TNBC)- Cytotoxic drug: The camptothecin-derived agent, SN-38, a topoisomerase I inhibitor act by interfering with the replicative capacity of cancer cells.-Linker: A hydrolyzable linker, with a short PEGylated unit.
How do Trodelvy, Trastuzumab emtansine (Kadcyla) and Trastuzumab deruxtecan (Enhertu) compare to eachother?
How likely would you be to use Trodelvy, judging by the clinical trial results to date?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
